ClinicalTrials.gov
ClinicalTrials.gov Menu

Effects of Treatments on Atopic Dermatitis

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01631617
Recruitment Status : Recruiting
First Posted : June 29, 2012
Last Update Posted : November 5, 2018
Sponsor:
Information provided by (Responsible Party):
National Institutes of Health Clinical Center (CC) ( National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) )

June 28, 2012
June 29, 2012
November 5, 2018
September 18, 2012
June 30, 2020   (Final data collection date for primary outcome measure)
Characterize microbiome alterations [ Time Frame: 2 weeks ]
Difference in Shannon Diversity Indices (SDI) from baseline to day 14.
To characterize microbiome alterations in healthy adult volunteers (Cohorts 1 and 2) and pediatric patients with AD and associated active bacterial infection (Cohort 3) after treatment. [ Time Frame: 2 weeks ]
Complete list of historical versions of study NCT01631617 on ClinicalTrials.gov Archive Site
Not Provided
To obtain samples from healthy adult volunteers to evaluate and refine genomic analysis of human microbes. To examine how different treatments may alter the human microbiome. [ Time Frame: 48 weeks ]
Not Provided
Not Provided
 
Effects of Treatments on Atopic Dermatitis
Effects of Treatments on the Microbiome in Healthy Volunteers and Patients With Atopic Dermatitis

Background:

- Atopic dermatitis, or eczema, is a chronic skin disorder. Patients sometimes have infections with S. aureus bacteria. Researchers want to study how eczema treatments affect the number and the type of bacteria on the skin.

Objectives:

- To study the effect of eczema treatments on skin bacteria.

Eligibility:

  • Individuals between 2 and 25 years of age who have moderate to severe atopic dermatitis.
  • Healthy volunteers between 18 and 40 years of age with no history of eczema.

Design:

  • Participants will be screened with a physical exam and medical history. Research samples will be collected. Skin biopsies may also be performed.
  • All participants will be assigned to one of several study groups.
  • This study will last for up to 1 year. Healthy volunteers must not have taken antibiotics in the year before the start of the study.
  • All participants will have regular study visits during their 1-year participation. More research samples will be collected at these visits.

BACKGROUND:

  • The use of antibiotics has revolutionized medicine, yet the impact of antimicrobials on the human microbiome is incompletely understood.
  • Antimicrobial treatments, including topical and systemic antibiotics, are highly effective and are frequently used to manage disease flares of AD. Concomitant use of dilute bleach baths reduces the clinical severity of AD in patients with clinical signs of bacterial skin infections.
  • The longitudinal impact of various antimicrobials on the human microbiome, particularly in skin, has not been systematically investigated.

OBJECTIVES:

Primary:

-To characterize microbiome alterations in healthy adult volunteers (Cohorts 1 and 2) and patients with AD (Cohort 3) after antimicrobial treatments.

ELIGIBILITY:

  • All subjects must be co-enrolled in NIH protocol 08-HG-0059
  • (Cohorts 1 and 2) Healthy volunteers aged 18 to 50 years with no history of AD
  • (Cohort 1 and 2) No prior use of systemic antibiotics in preceding 12 months
  • (Cohort 3) Subjects 2-50 years with atopic dermatitis with symptoms of active bacterial infection
  • (Cohort 3) Objective SCORAD (SCORing Atopic Dermatitis) score of greater than or equal to 15 indicating moderate-to-severe disease

DESIGN:

  • A prospective, interventional, longitudinal study examining changes in microbiome resulting from randomized, placebo-controlled, investigator-blinded antimicrobial treatments.
  • Subjects in Cohort 1 will be randomized to take one of 4 open label antibiotic regimens.
  • Subjects from Cohort 2 will be will be randomized to one of four possible blinded treatment combinations of study baths and antibiotics.
  • Subjects in Cohort 3 will be randomized to a cephalexin regimen with or without study baths.
  • All subjects will undergo longitudinal microbiome sampling.
  • AD patients will undergo clinical assessment to determine responses of skin infections to treatment.
Interventional
Phase 2
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single (Investigator)
Primary Purpose: Treatment
Dermatitis, Atopic
  • Drug: Trimethoprim/sulfamethoxazole (TMP/SMZ)
    800/160 orally every 12 hours for 14 days
  • Drug: Cephalexin
    500 mg orally every 8 hours for 14 days
  • Drug: Doxycycline
    20 mg orally every 12 hours for 56 days or 100 mg orally every 12 hours for 56 days
  • Other: Sodium hypochlorite
    6 % dilute bleach
  • Other: Placebo capsules
    Capsule orally every 8 hours daily for 14 days
  • Other: Placebo Sodium hypochlorite
    Three times a week for 14 days
  • Active Comparator: 1A/Cephalexin
    Cephalexin + Placebo bleach
    Intervention: Drug: Cephalexin
  • Active Comparator: 1B/TMP/SMX
    TMP/SMZ DS 800 /160 orally every 12 hours for 14 days
    Intervention: Drug: Trimethoprim/sulfamethoxazole (TMP/SMZ)
  • Active Comparator: 1C/Doxycycline 100
    Doxycycline 100 mg orally every 12 hours for 56 days
    Interventions:
    • Drug: Cephalexin
    • Other: Sodium hypochlorite
  • Active Comparator: 1D/Doxycycline 20
    Doxycycline 20 mg orally every 12 hours for 56 days
    Intervention: Drug: Doxycycline
  • Active Comparator: 2A/Cephalexin + Dilute bleach
    Systemic antibiotics (Cephalexin) + dilute bleach study bath liquid
    Interventions:
    • Drug: Cephalexin
    • Other: Sodium hypochlorite
  • Placebo Comparator: 2B/Cephalexin + Placebo bleach
    Systemic antibiotics (Cephalexin) + placebo study bath liquid
    Interventions:
    • Drug: Cephalexin
    • Other: Placebo Sodium hypochlorite
  • Placebo Comparator: 2C/Placebo capsules + Dilute bleach
    Placebo capsules + dilute bleach study bath liquid
    Interventions:
    • Other: Sodium hypochlorite
    • Other: Placebo capsules
  • Placebo Comparator: 2D/Placebo capsules + Placebo bleach
    Placebo capsules + placebo study bath liquid
    Interventions:
    • Other: Placebo capsules
    • Other: Placebo Sodium hypochlorite
  • Active Comparator: 3A/Cephalexin + Dilute bleach
    Systemic antibiotics (Cephalexin) + dilute bleach study bath liquid
    Interventions:
    • Drug: Cephalexin
    • Other: Sodium hypochlorite
  • Placebo Comparator: 3B/Cephalexin + Placebo bleach
    Systemic antibiotics (Cephalexin) + placebo study bath liquid
    Interventions:
    • Drug: Cephalexin
    • Other: Placebo Sodium hypochlorite
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
130
105
June 30, 2020
June 30, 2020   (Final data collection date for primary outcome measure)
  • INCLUSION CRITERIA:

Cohorts 1 and 2: Healthy Volunteers

Males and females aged 18-50 years.

  • Subjects must participate fully and be willing to comply with the procedures of the protocol
  • Subjects must be co-enrolled in NIH protocol 08-HG-0059
  • Ability of subject to understand and provide written informed consent.
  • Access to bathing facilities
  • Ability to swallow capsules or tablets

Cohort 3: Atopic Dermatitis Patients

  • Subjects must be aged 2-50 years.
  • Subjects must be co-enrolled in NIH protocol 08-HG-0059
  • Subjects must have a diagnosis of atopic dermatitis on the basis of the criteria defined by UK Working Party s Diagnostic Criteria for Atopic Dermatitis
  • Subjects must have a primary care provider
  • Subjects must have an Objective SCORAD (SCORing Atopic Dermatitis) of greater than or equal to 15 indicating AD severity of moderate to severe
  • Prior to initiation of randomized treatment, subjects must have signs of bacterial skin infections (skin weeping, crusting, and/or pustules)
  • Access to bathing facilities
  • All subjects and/or their Legally Authorized Representative (LAR) must have the ability and agree to participate fully and comply with

the procedures of the protocol and provide informed consent. Pediatric patients will be included in age appropriate discussions and

age appropriate assent will be obtained in accordance with NIH guidelines.

EXCLUSION CRITERIA:

Cohorts 1 and 2: Healthy Volunteers

  • Does not meet inclusion criteria
  • Any female with symptoms and/or serum hormone levels consistent with perimenopause
  • Use of systemic antibiotics in 12 months preceding baseline sampling
  • Use of swimming pools, hot tubs, or whirlpools in 7 days preceding baseline sampling
  • Use of topical or oral complementary/alternative medicine (CAM) agents within 4 weeks of initiation of treatment
  • Known allergic reaction to sulfa, beta-lactam, or tetracycline class drugs; or lidocaine or epinephrine
  • Family history of toxic epidermal necrolysis
  • Known allergy or sensitivity to sodium hypochlorite (NaOCl)
  • History of AD and asthma
  • Inability to comply with the requirements of the protocol
  • Pregnant or lactating
  • Subjects with a primary or acquired immunodeficiency, including HIV seropositiviy
  • Any chronic past or present medical illness, including chronic skin diseases like psoriasis
  • Subjects receiving or planning to receive an IND agent, ultraviolet light therapy, monoclonal antibodies, or systemic immunosuppressants
  • Subjects who provide direct healthcare or reside in healthcare facilities or in non-hospital settings such as clinics, assisted living facilities, homeless shelters, jails and prisons as well as subjects with frequent exposure to laboratory animals

Cohort 3: Atopic Dermatitis Patients

  • Does not meet inclusion criteria
  • Any female with symptoms and/or serum hormone levels consistent with perimenopause
  • Known allergic reaction to beta-lactam class drugs, lidocaine, or epinephrine
  • Family history of toxic epidermal necrolysis
  • Known allergic reaction to sodium hypochlorite (NaOCl)
  • Use of systemic antibiotics within 8 weeks, or topical antibiotics on intended sampling sites within 3 weeks, prior to baseline sampling
  • Use of topical corticosteroids on all intended sampling sites within 7 days, prior to baseline sampling
  • Use of topical or oral CAM agents within 4 weeks of initiation of treatment
  • Subjects with known primary or acquired immunodeficiency
  • Subjects with unstable or uncontrolled medical conditions that could require hospitalization during the initial month of the study or who have been hospitalized for treatment of these conditions in the one month prior to baseline sampling
  • Subjects receiving or planning to receive an IND agent, ultraviolet light therapy, monoclonal antibodies, or systemic immunosuppressants within 7 days or 5 half-lives (whichever is the longer time period) of initiating treatment on this protocol
  • Subjects who are currently receiving or have received chemotherapy or radiation for treatment of malignancies within the previous 6 months
  • Pregnancy or lactating
  • Pregnant or lactating females in all cohorts are excluded from participating due to the potential effects of the above listed antimicrobials on the developing human fetus or nursing infant; listed in Sections 11.1 through 11.5. Females of childbearing potential must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation. Should a woman become pregnant or suspect she is pregnant while she is participating in this study, she should inform her treating physician immediately. Lactating mothers will discontinue breastfeeding prior to study enrollment.
  • Smokers and subjects who use smokeless tobacco products are excluded in all cohorts due to tobacco s unknown impact on human oral mucosa and microflora.
Sexes Eligible for Study: All
2 Years to 50 Years   (Child, Adult)
Yes
Contact: Bryan P Higgins, R.N. (240) 760-6049 bryan.higgins@nih.gov
Contact: Heidi H Kong, M.D. (301) 827-2460 konghe@mail.nih.gov
United States
 
 
NCT01631617
120159
12-AR-0159
Not Provided
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Not Provided
National Institutes of Health Clinical Center (CC) ( National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) )
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Not Provided
Principal Investigator: Heidi H Kong, M.D. National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
National Institutes of Health Clinical Center (CC)
October 24, 2018

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP